alexa Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Oncology

Oncology

Archives of Surgical Oncology

Author(s): Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR

Abstract Share this page

Abstract BACKGROUND: Few studies have reported on late declines and long-term health-related quality of life (HRQOL) after prostate cancer (PCa) treatment. OBJECTIVE: We assessed long-term HRQOL following various treatments for localized PCa. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of HRQOL up to 10 yr after treatment used a prospectively accrued, nationwide PCa registry that collects longitudinal patient-reported HRQOL. INTERVENTION: Various primary treatments for localized PCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The Medical Outcomes Studies 36-item Short Form and the University of California, Los Angeles, Prostate Cancer Index characterized physical function, mental health, and sexual, urinary, and bowel function and bother. Repeated measures mixed-model analysis assessed change in HRQOL by treatment over time, and logistic regression was used to measure the likelihood of a clinically significant decline in HRQOL. RESULTS AND LIMITATIONS: Among 3294 men, 1139 (34\%) underwent nerve-sparing radical prostatectomy (NSRP), 860 (26\%) underwent non-NSRP, 684 (21\%) underwent brachytherapy, 386 (12\%) underwent external beam radiotherapy, 161 (5\%) underwent primary androgen deprivation therapy, and 64 (2\%) pursued watchful waiting/active surveillance. Median follow-up was 74 mo (interquartile range: 50-102). Most treatments resulted in early declines in HRQOL, with some recovery over the next 1-2 yr and a plateau in scores thereafter. Surgery had the largest impact on sexual function and bother and on urinary function, radiation had the strongest effect on bowel function, and androgen deprivation therapy had the strongest effect on physical function. The main limitation was attrition among the cohort. CONCLUSIONS: Although most men experience initial declines in HRQOL in the first 2 yr after treatment, there is little change from 3 to 10 yr and most differences between treatments attenuated over time. PATIENT SUMMARY: Various treatments for prostate cancer result in a distinct constellation of adverse effects on health-related quality of life, which may have a long-term impact. These findings are helpful regarding shared decision making over choice of primary treatment. Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved. This article was published in Eur Urol and referenced in Archives of Surgical Oncology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords